Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Evolent Health (EVH) and Cormedix (CRMD)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Altimmune (ALT – Research Report), Evolent Health (EVH – Research Report) and Cormedix (CRMD – Research Report) with bullish sentiments.

Altimmune (ALT)

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Altimmune, with a price target of $24.00. The company’s shares closed last Thursday at $7.72.

According to TipRanks.com, Wolleben is a 4-star analyst with an average return of 6.2% and a 39.7% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Sagimet Biosciences, Inc. Class A, and DBV Technologies SA – American.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Altimmune with a $23.20 average price target.

See the top stocks recommended by analysts >>

Evolent Health (EVH)

JMP Securities analyst Constantine Davides maintained a Buy rating on Evolent Health today and set a price target of $34.00. The company’s shares closed last Thursday at $26.96.

According to TipRanks.com, Davides is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -28.9% and a 18.4% success rate. Davides covers the Healthcare sector, focusing on stocks such as Cross Country Healthcare, AMN Healthcare Services, and Privia Health Group.

Evolent Health has an analyst consensus of Strong Buy, with a price target consensus of $45.50.

Cormedix (CRMD)

JMP Securities analyst Jason Butler reiterated a Buy rating on Cormedix today and set a price target of $19.00. The company’s shares closed last Thursday at $5.41.

According to TipRanks.com, Butler has 0 stars on 0-5 stars ranking scale with an average return of -5.7% and a 38.7% success rate. Butler covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Aquestive Therapeutics, and Vigil Neuroscience Inc.

Cormedix has an analyst consensus of Strong Buy, with a price target consensus of $12.67.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALT:

• Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update
• Altimmune call volume above normal and directionally bullish
• Class Action Filed Against Altimmune, Inc. (ALT) Seeking Recovery for Investors – Contact Levi & Korsinsky LLP
• Altimmune to Participate at Two Upcoming Investor Conferences
• Is ALT a Buy, Before Earnings?